Finance

Beta
Lists
000220:KRX
Yuyu Pharma Inc
₩3,820.00
-0.65%
(-25.00) 1D
Jun 11, 9:29:38 AM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 000220...
Open
₩3,840
High
₩3,845
Low
₩3,770
Mkt. cap
77.15B
Avg. vol.
491.18K
Volume
5.87K
Dividend
3.01%
Quarterly dividend
₩29
Ex-dividend date
Dec 27, 2024
P/E ratio
7.67
52-wk high
₩5,100
52-wk low
₩3,580
EPS
₩498
Shares outstanding
17.03M
No. of employees
254
Open
₩3,840
High
₩3,845
Low
₩3,770
Mkt. cap
77.15B
Avg. vol.
491.18K
Volume
5.87K
Dividend
3.01%
Quarterly dividend
₩29
Ex-dividend date
Dec 27, 2024
P/E ratio
7.67
52-wk high
₩5,100
52-wk low
₩3,580
EPS
₩498
Shares outstanding
17.03M
No. of employees
254
News stories
From sources across the web
About Yuyu Pharma Inc
CEO-
Employees254
Founded1941
Headquarters-
SectorPharmaceutical industry
Websiteyuyu.co.kr
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
35.85B
37.79B
34.34B
35.54B
Cost of goods sold
22.50B
23.00B
22.54B
21.04B
Cost of revenue
22.50B
23.00B
22.54B
21.04B
Research and development expenses
861.12M
914.90M
1.15B
703.42M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9.61B
8.71B
10.17B
8.95B
Operating expense
11.10B
9.81B
11.93B
10.19B
Total operating expenses
33.60B
32.81B
34.47B
31.24B
Operating income
2.25B
4.99B
-129.07M
4.30B
Other non operating income
2.15B
56.65M
-1.13B
863.61M
EBT including unusual items
1.01B
4.82B
202.03M
3.97B
EBT excluding unusual items
3.63B
4.77B
-1.11B
4.99B
Income tax expense
414.83M
504.29M
-1.00B
620.45M
Effective tax rate
41.21%
10.46%
-496.97%
15.62%
Other operating expenses
107.18M
18.27M
76.24M
40.94M
Net income
199.06M
3.98B
1.39B
3.49B
Net profit margin
0.56%
10.52%
4.03%
9.82%
Earnings per share
-
-
-
-
Interest and investment income
257.20M
136.07M
529.96M
286.44M
Interest expense
-668.25M
-540.35M
-547.07M
-474.32M
Net interest expenses
-411.05M
-404.28M
-17.11M
-187.88M
Depreciation and amortization charges
409.71M
320.96M
403.34M
334.87M
EBITDA
3.67B
6.34B
1.33B
5.68B
Gain or loss from assets sale
-3.35M
-13.34M
-
-499.00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer